Combination of Low Dose Antiestrogens With Omega-3 Fatty Acids for Prevention of Hormone-independent Breast Cancer
Phase of Trial: Phase II
Latest Information Update: 01 Jun 2017
At a glance
- Drugs Omega-3-acid ethyl esters (Primary) ; Raloxifene (Primary)
- Indications Breast cancer
- Focus Biomarker; Pharmacodynamics
- 10 Jun 2017 Biomarkers information updated
- 30 Jan 2013 Planned end date changed from 1 Oct 2012 to 1 Oct 2013 as reported by ClinicalTrials.gov.
- 30 Jan 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.